VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J. 2015 Dec; 46(6):1740-50.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
Antimetabolites
Belgium
Canada
Carbon Monoxide
Chemokine CCL2
Disease Progression
Dose-Response Relationship, Drug
Double-Blind Method
Female
Germany
Humans
Idiopathic Pulmonary Fibrosis
Male
Middle Aged
Netherlands
Pulmonary Diffusing Capacity
Quality of Life
Treatment Outcome
United States
Vital Capacity
authors with profiles
FERNANDO MARTINEZ